Sponsor:
Washington University School of Medicine
Code:
NCT07593079
Conditions
Prostate Cancer
Recurrent Prostate Cancer
Metastatic Prostate Cancer
Prostate Cancer Recurrent
Prostate Cancer Metastatic
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bicalutamide
Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography
18F-rhPSMA-7.3
PROSTest
Brief summary:
Conditions
Prostate Cancer
Recurrent Prostate Cancer
Metastatic Prostate Cancer
Prostate Cancer Recurrent
Prostate Cancer Metastatic
Study ID
NCT07593079
Start date
Nov 16, 2026
Status verified date
Nov, 2026
Completion date
Feb 28, 2028
Anticipated
Primary completion date
Dec 14, 2027
Anticipated
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
20 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Diagnostic
Arms
active comparator: Group A: Baseline PSMA PET/CT only with standard of care bicalutamide
experimental: Group B: PSMA PET/CT after 2 weeks of standard of care bicalutamide
Interventions
Bicalutamide
Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography
18F-rhPSMA-7.3
PROSTest
Primary outcome measure
Central contacts
Locations
Washington University School of Medicine
Recruiting
St Louis, Missouri, United States, 63110
Contacts
Principal Investigator:
Vikas Prasad, MD, PhD
Sponsor
Washington University School of Medicine
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.